We are pleased to share that Cellis has received funding under the project titled:
“Preparation of the technology for clinical trials of the innovative MDC-735 cell based therapy.”
This initiative is supported by the European Funds for a Modern Economy (FENG) as part of Poland’s National Recovery and Resilience Plan (KPO), financed by NextGenerationEU.
The grant will enable us to prepare the regulatory, technical, and manufacturing groundwork for clinical trials of MDC-735, our macrophage-drug conjugate therapy for solid tumors. The project covers regulatory submissions in Poland, Germany, and Switzerland, consultations with the FDA, and GMP manufacturing of a stable allogeneic product.
We thank all institutions involved for their support of innovative oncology solutions that can improve the lives of patients worldwide.
